Lisata Therapeutics reports strong 1Q performance, cash to support operations into 2026 Lisata Therapeutics Inc (NASDAQ:LSTA) has ended its first quarter of 2024 with nearly $43.3 million in cash to fund its…
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma Achieves critical first step toward priority review voucher Achieves critical first step toward priority review voucher…
Earnings call: Lisata Therapeutics reports on clinical trials and finances By Investing.com Earnings call: Lisata Therapeutics reports on clinical trials and finances…